A fundamental study for vaccine therapy in myasthenia gravis
Project/Area Number |
13670645
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Neurology
|
Research Institution | Tottori University |
Principal Investigator |
ARAGA Shigeru Tottori University, Faculty of Medicine, Associate Professor, 医学部, 助教授 (40193065)
|
Project Period (FY) |
2001 – 2002
|
Project Status |
Completed (Fiscal Year 2002)
|
Budget Amount *help |
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 2002: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2001: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
Keywords | Myasthenia gravis / complementary peptide / anti-idiotype antibody / acetylcholine receptor / TE671 |
Research Abstract |
Using KM^<TM> mouse that can produce human immunoglobulins, we have developed the idiotype antibodies and its anti-idiotype antibodies for the treatment of myasthenia gravis(MG). By immunization of KM^<TM> mice with purified human alpha-acetylcholine receptor(AChR), we could obtain 15 mAbs. Twelve of 15 clones have a strong affinity against the AChR. Two of them showed the AChR defradation using^<125> I bungarotoxin binding assay. We also could obtain two mAbs against the complementary peptide(CHIVVKEPIWIVIATHF-COOH) for human AChR61-76 amino acid residues. Using Fab' of these mAb, we will try to check the idiotype antibodies in patients with MG.
|
Report
(3 results)
Research Products
(15 results)